Drug Trials Snapshot - CABENUVA

A new DRUG TRIALS SNAPSHOT is now available. CABENUVA is a 2-drug co-packaged product for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who are virologically supressed and need to replace their current HIV-1 medicines. HIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS). CABENUVA is an injection. Two co-packaged injections (cabotegravir and rilpivirine) are injected by healthcare provider into the muscle of each side of buttocks one time every month. Before receiving first injection doses of CABENUVA, patients need to take 1 VOCABRIA (cabotegravir) tablet and 1 EDURANT (rilpivirine) tablet once a day for one month to ensure the medications are well-tolerated.   See more Drug Trials Snapshots or contact us with questions at Snapshots@fda.hhs.gov     Manage Subscriptions  |  Unsubscribe All  |  Help This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA